Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

47 results about "Syk kinase" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Syk is a nonreceptor protein tyrosine kinase that is involved in signal transduction in immune cells bearing Fcγ-activating receptors, including macrophages, mast cells, B cells, neutrophils and synoviocytes.

Kinase inhibitors

InactiveUS20140057915A1Weak affinityImproved profileBiocideOrganic active ingredientsTyrosineP38 Mitogen Activated Protein Kinase

There are provided compounds of formula I,wherein R, R1, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

Kinase inhibitors

Kinase inhibitors

Owner:RESPIVERT +1

Pyrazole derivatives as p38 MAP inhibitors

InactiveUS9249125B2Weak affinityImproved profileSenses disorderOrganic chemistryUveitisUlcerative colitis

Compounds of formula (I):wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.

Owner:RESPIVERT +1

1,6 naphthridines useful as inhibitors of syk kinase

InactiveUS20090171089A1Organic chemistryAntipyreticDiseaseEnzyme inhibitor

Disclosed are compounds of formula (I):wherein R3, R5, R7 and R8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

1,6 naphthridines useful as inhibitors of syk kinase

1,6 naphthridines useful as inhibitors of syk kinase

1,6 naphthridines useful as inhibitors of syk kinase

Owner:BOEHRINGER INGELHEIM PHARMA INC

Pyrazine kinase inhibitors

ActiveUS20130131040A1Inhibitory activityBiocideSenses disorderSyk kinaseEnzyme inhibitor

Provided are pyrazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

Pyrazine kinase inhibitors

Pyrazine kinase inhibitors

Pyrazine kinase inhibitors

Owner:ALEXION PHARM INC

Kinase inhibitors

InactiveUS20150166483A1Maintain good propertiesSenses disorderOrganic chemistryMedicineP38 Mitogen Activated Protein Kinase

There is provided a compound of formula I,which compound has antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases, e.g., Src and Lck) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

Kinase inhibitors

Kinase inhibitors

Owner:RESPIVERT +1

Pyrazole derivatives as p38 map inhibitors

InactiveUS20150203475A1Weak affinityImproved profileBiocideOrganic active ingredientsUveitisUlcerative colitis

Compounds of formula (I):wherein R1, R2, J, Q, V, X, Y and Z are defined herein are disclosed. The compounds are inhibitors of the family of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha sub-type thereof, and of Syk kinase and the Src family of tyrosine kinases. The compounds may be used in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, in particular inflammatory diseases of the lung, such as asthma and COPD, as well as those of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease and of the eye, such as uveitis.

Pyrazole derivatives as p38 map inhibitors

Pyrazole derivatives as p38 map inhibitors

Pyrazole derivatives as p38 map inhibitors

Owner:RESPIVERT +1

Kinase inhibitors

ActiveUS20160340375A1Good anti-inflammatory propertyMaintain good propertiesGroup 4/14 element organic compoundsAntipyreticMedicineTyrosine

There are provided compounds of formula I.wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

Kinase inhibitors

Kinase inhibitors

Owner:OXULAR ACQUISITIONS LTD

Kinase inhibitors

ActiveUS20160340343A1Maintain good propertiesOrganic active ingredientsGroup 4/14 element organic compoundsDiseaseTyrosine

There are provided compounds of formula I,wherein R1 to R5, X1, X2, Ar, L, E, A, A1, G and G1 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

Kinase inhibitors

Kinase inhibitors

Owner:OXULAR ACQUISITIONS LTD

Kinase inhibitors

ActiveUS20160318909A1Weak affinityImproved profileOrganic active ingredientsAntipyreticTyrosineP38 Mitogen Activated Protein Kinase

There are provided compounds of formula I,wherein:Y represents NR2R3;one of R2 and R3 represents —[C2-4 alkylene-O]1-12—[C2-4 alkylene]-R2a and the other of R2 andR3 has a meaning given in the description; andR, R1, R2a, Ra, Rb, Q, X and Y have meanings given in the description,which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

Kinase inhibitors

Kinase inhibitors

Owner:OXULAR ACQUISITIONS LTD

2, 6-diamino- pyrimidin- 5-yl-carboxamides as SYK or JAK kinases inhibitors

ActiveCN102066339AOrganic active ingredientsNervous disorderAutoimmune diseasePlatelet inhibition

The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods ofinhibilion the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as cardiovascular disease, inflammatory disease and autoimmune disease and cell proliferative disorder. Formula (I) Y1 is selected from the group consisting of: (a) and (b); Z is O or S; D1 is selected from the group consisting of: (a) phenyl substituted with a group, R5 (b) naphthyl (c) C3-8cycloalkyl (d) heteroaryl (e) heterocyclyl.

2, 6-diamino- pyrimidin- 5-yl-carboxamides as SYK or JAK kinases inhibitors

2, 6-diamino- pyrimidin- 5-yl-carboxamides as SYK or JAK kinases inhibitors

2, 6-diamino- pyrimidin- 5-yl-carboxamides as SYK or JAK kinases inhibitors

Owner:PORTOLA PHARMA INC

Combination therapy with syk kinase inhibitor

InactiveUS20090088371A1BiocideOrganic active ingredientsMedicineTyrosine-kinase inhibitor

The invention encompasses methods of increasing platelet levels in a patient having or at risk for immune thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist, and methods of treating thrombocytopenia comprising co-administering a Syk kinase inhibitor and a thrombopoietin receptor agonist to a patient in need thereof, as well as pharmaceutical compositions for use in these methods.

Combination therapy with syk kinase inhibitor

Combination therapy with syk kinase inhibitor

Combination therapy with syk kinase inhibitor

Owner:RIGEL PHARMA

Kinase inhibitor

ActiveUS9499486B2Maintain good propertiesSenses disorderAntipyreticIntestinal structureTyrosine

There is provided a compound of formula I,which compound has anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitor

Kinase inhibitor

Kinase inhibitor

Owner:OXULAR ACQUISITIONS LTD

Inhibitors of syk and JAK protein kinases

ActiveUS8063058B2BiocideOrganic chemistryThrombusPharmaceutical Substances

The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.

Inhibitors of syk and JAK protein kinases

Inhibitors of syk and JAK protein kinases

Inhibitors of syk and JAK protein kinases

Owner:ALEXION PHARMA INC

Selective kinase inhibitors

InactiveUS20140323418A1Esterified saccharide compoundsBiocideKinaseEnzyme inhibitor

Provided are pyrimidine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

Selective kinase inhibitors

Selective kinase inhibitors

Selective kinase inhibitors

Owner:ALEXION PHARMA INC

Substituted pyrazine-2-carboxamide kinase inhibitors

ActiveUS8877760B2Inhibitory activityBiocideOrganic active ingredientsPyrazineKinase inhibition

Provided are substituted pyrazine-2-carboxamide compounds of Formula I:useful for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

Substituted pyrazine-2-carboxamide kinase inhibitors

Substituted pyrazine-2-carboxamide kinase inhibitors

Substituted pyrazine-2-carboxamide kinase inhibitors

Owner:ALEXION PHARMA INC

Substituted pyrimidinyl kinase inhibitors

ActiveUS20150259328A1BiocideOrganic chemistryKinaseEnzyme inhibitor

Provided are substituted pyrimidinyl compounds for inhibition of JAK and / or Syk kinase, pharmaceutical compositions thereof, methods for inhibiting JAK and / or Syk kinase activity, and methods for treating conditions mediated at least in part by JAK and / or Syk kinase activity.

Substituted pyrimidinyl kinase inhibitors

Substituted pyrimidinyl kinase inhibitors

Substituted pyrimidinyl kinase inhibitors

Owner:ALEXION PHARMA INC

Urea derivatives useful as kinase inhibitors

ActiveUS9890185B2Good anti-inflammatory propertyMaintain good propertiesSenses disorderAntipyreticUrea derivativesMedicine

There are provided compounds of formula I, wherein R1, R1A, R1C to R1E, Ra, Rb, X1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Urea derivatives useful as kinase inhibitors

Urea derivatives useful as kinase inhibitors

Urea derivatives useful as kinase inhibitors

Owner:OXULAR ACQUISITIONS LTD

Kinase inhibitor

ActiveUS20170029378A1Maintain good propertiesSenses disorderAntipyreticIntestinal structureTyrosine

There is provided a compound of formula VIIa,wherein Qx represents —C(O)O—C1-4 alkyl, or a salt or protected derivative thereof, and other compounds that are useful in the preparation of compounds that have antiinflammatory activity (e.g., through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitor

Kinase inhibitor

Kinase inhibitor

Owner:OXULAR ACQUISITIONS LTD

1,2,4-triazine-6-carboxamide kinase inhibitors

ActiveUS20130345191A1BiocideNervous disorderMolecular biologySyk kinase

Provided are triazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

1,2,4-triazine-6-carboxamide kinase inhibitors

1,2,4-triazine-6-carboxamide kinase inhibitors

1,2,4-triazine-6-carboxamide kinase inhibitors

Owner:ALEXION PHARMA INC

Pyrazine Kinase Inhibitors

ActiveUS20140309209A1Inhibitory activityOrganic active ingredientsBiocidePyrazineKinase

Provided are pyrazine compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibition Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

Pyrazine Kinase Inhibitors

Pyrazine Kinase Inhibitors

Pyrazine Kinase Inhibitors

Owner:ALEXION PHARMA INC

New Signaling Molecule Involved in Ultraviolet Damage to Skin

ActiveUS20130072572A1Lower Level RequirementsBiocideCosmetic preparationsDiseaseMammal

The present invention includes a method of detecting ultraviolet radiation (UVR)-induced skin damage in a mammal. The present invention also includes a method of identifying a mammal at risk of developing U VR-induced skin damage, photoaging, or photocarcinogenesis. The present invention further includes a method of inhibiting UVR-induced skin damage in a mammal at risk of developing U VR-induced skin damage. The present invention also includes a method of reducing the level of Syk kinase in the skin of a mammal. The present invention further includes methods of treating or diagnosing a disease associated with a change of Syk kinase expression in the skin in a mammal.

New Signaling Molecule Involved in Ultraviolet Damage to Skin

New Signaling Molecule Involved in Ultraviolet Damage to Skin

New Signaling Molecule Involved in Ultraviolet Damage to Skin

Owner:DREXEL UNIV

Benzamides and nicotinamides as Syk modulators

ActiveUS8846928B2Inhibitory activityBiocideSenses disorderPlatelet inhibitionPlatelet aggregation

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

Benzamides and nicotinamides as Syk modulators

Benzamides and nicotinamides as Syk modulators

Benzamides and nicotinamides as Syk modulators

Owner:ALEXION PHARMA INC

Kinase inhibitors and their uses

ActiveUS8053434B2BiocideNervous disorderKinase activityStructural formula

The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and / or prevent diseases associated with inappropriate kinase activity. The compounds of the present invention are according to structural formula (I):or a salt or N-oxide thereof, whereinB is selected from

Kinase inhibitors and their uses

Kinase inhibitors and their uses

Kinase inhibitors and their uses

Owner:RIGEL PHARMA

Benzamides and nicotinamides as syk modulators

ActiveUS20150038492A1Inhibitory activityBiocideSenses disorderPlatelet inhibitionEnzyme inhibitor

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

Benzamides and nicotinamides as syk modulators

Benzamides and nicotinamides as syk modulators

Benzamides and nicotinamides as syk modulators

Owner:ALEXION PHARMA INC

1,6 naphthyridines useful as inhibitors of SYK kinase

InactiveUS7678911B2BiocideOrganic chemistryDiseaseStereochemistry

Disclosed are compounds of formula (I):wherein R3, R5, R7 and R8 are defined herein, which are useful as inhibitors SYK kinase and are thus useful for treating diseases resulting from inappropriate mast cell activation, which include allergic and inflammatory diseases. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

1,6 naphthyridines useful as inhibitors of SYK kinase

1,6 naphthyridines useful as inhibitors of SYK kinase

1,6 naphthyridines useful as inhibitors of SYK kinase

Owner:BOEHRINGER INGELHEIM PHARMA INC

Method for sustaining enos activity

InactiveUS20060127385A1FibrinogenPeptide/protein ingredientsClot retractionMedicine

The present invention is directed to methods for sustaining eNOS activity to inhibit platelet aggregation, clot retraction, and enhance fibrinolysis. One embodiment of the invention provides methods of treating thrombosis by inhibiting the activity of the syk kinase. Another embodiment provides assays for the discovery of improved compounds to treat thrombosis, by screening for compounds which sustain eNOS activity. Yet another embodiment provides assays for the discovery of improved compounds to treat thrombosis, by identifying inhibitors of calpain and IIbIIIa by screening for compounds which act through calpain or IIbIIIa to sustain eNOS activity. Yet another embodiment provides for enhancing fibrinolysis, by inhibiting the activity of the syk kinase or calpain.

Method for sustaining enos activity

Method for sustaining enos activity

Method for sustaining enos activity

Owner:SARKAR SIBAJI

Syk kinase inhibitors as treatment for malaria

InactiveUS20140309233A1Easily toleratedBiocideHydroxy compound active ingredientsDiseaseMalaria

The disclosure relates to methods, compositions, and kits for treatment of parasite-mediated disease. In one embodiment, the disclosure relates to compounds, compositions, methods and kits for the treatment of malaria. In still another embodiment, the disclosure relates to a method for treating malaria comprising the use of a Syk kinase inhibitor.

Syk kinase inhibitors as treatment for malaria

Syk kinase inhibitors as treatment for malaria

Syk kinase inhibitors as treatment for malaria

Owner:PURDUE RES FOUND INC

Substituted pyrimidinyl kinase inhibitors

ActiveUS9676756B2Organic active ingredientsOrganic chemistryKinaseEnzyme inhibitor

Provided are substituted pyrimidinyl compounds for inhibition of JAK and / or Syk kinase, pharmaceutical compositions thereof, methods for inhibiting JAK and / or Syk kinase activity, and methods for treating conditions mediated at least in part by JAK and / or Syk kinase activity.

Substituted pyrimidinyl kinase inhibitors

Substituted pyrimidinyl kinase inhibitors

Substituted pyrimidinyl kinase inhibitors

Owner:ALEXION PHARMA INC

Substituted picolinamide kinase inhibitors

InactiveUS20140113931A1BiocideNervous disorderKinase activityEnzyme inhibitor

Provided are picolinamide compounds for inhibiting of Syk kinase, intermediates used in making such compounds, methods for their preparation, pharmaceutical compositions thereof, methods for inhibiting Syk kinase activity, and methods for treating conditions mediated at least in part by Syk kinase activity.

Substituted picolinamide kinase inhibitors

Substituted picolinamide kinase inhibitors

Substituted picolinamide kinase inhibitors

Owner:ALEXION PHARMA INC

Kinase inhibitors

ActiveUS9796742B2Maintain good propertiesSilicon organic compoundsAntipyreticTyrosineP38 Mitogen Activated Protein Kinase

There are provided compounds of formula I,wherein R1 to R5, X1, X2, Ar, L, A, A1, E and G have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Kinase inhibitors

Kinase inhibitors

Kinase inhibitors

Owner:OXULAR ACQUISITIONS LTD

Popular searches

Israpafant Protein kinase C Src family Tyrosine kinase Inflammatory bowel disease Enzyme Kinase Family Tyrosine kinase 2 Inflammatory skin disease Disease cause

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Patsnap Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Patsnap Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com